Get started
Author

Michael Schwitter

RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?
2014 · Richard Cathomas, Christian Rothermundt, et al. · Oncology · 44
PDF
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
2020 · Michael Mark, Patrizia Froesch, et al. · Cancer Immunology Immunotherapy · 18
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)
2024 · Ilaria Colombo, Kira-Lee Koster, et al. · European Journal of Cancer · 17
PDF
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
2023 · Silke Gillessen, Giuseppe Procopio, et al. · Journal of Clinical Oncology · 11
PDF
Effect of an interprofessional small-group communication skills training incorporating critical incident approaches in an acute care and rehabilitation clinic specialized for spinal cord injury and disorder
2022 · Anke Scheel-Sailer, Stephanie Eich, et al. · Frontiers in Rehabilitation Sciences · 10
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial
2025 · Gianmarco Leone, Francesco Orlando, et al. · JAMA Oncology · 9
Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested
2013 · Michael Schwitter, Regulo Rodriguez, et al. · Case Reports in Oncology · 9
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial
2024 · Anna M. Mc Laughlin, Dagmar Hess, et al. · Cancer Chemotherapy and Pharmacology · 8
PDF
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study
2023 · Nadia Harbeck, Denise Wrobel, et al. · Breast Care · 8
Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparison
2024 · Kristen Johnson, Barbara Stoffel, et al. · Supportive Care in Cancer · 6
PDF
Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE)
2019 · A Müller, AJ Templeton, et al. · Cancer Research · 3
24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial
2026 · Uwe Güth, Nicolette Hoefnagels, et al. · The Breast · 2
Abstract P3-11-22: Extended adjuvant neratinib in HER2+/HR+ early breast cancer (eBC) in clinical routine – interim analysis of the multinational, prospective, non-interventional study ELEANOR (n=300)
2025 · Diana Lüftner, Denise Wrobel, et al. · Clinical Cancer Research · 2
75P Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+ / HR+ early breast cancer (eBC)
2022 · N. Harbeck, D. Wrobel, et al. · Annals of Oncology · 2
TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16)
2025 · Marian Klose, Ilaria Colombo, et al. · Clinical Pharmacokinetics · 1
35P TLD-1 – A novel liposomal doxorubicin formulation, in patients with advanced solid tumors: Final results of a multicenter, open-label, cross-over phase I study (SAKK 65/16)
2025 · M. Joerger, M. Klose, et al. · ESMO Open · 1
PDF
2104P Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
2023 · K. Johnson, B. Stoffel, et al. · Annals of Oncology · 1
PDF
Abstract P2-01-01: Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine
2023 · Rupert Bartsch, Nadia Harbeck, et al. · Cancer Research · 1
TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
2022 · Dagmar Hess, Ilaria Colombo, et al. · Journal of Clinical Oncology · 1
Patient Selection for Partial Breast Irradiation in the Era of Sentinel Lymph Node Biopsy Omission: A Narrative Review
2026 · Efstratios Karagiannis, Roger von Moos, et al. · Cancers
Abstract PS5-06: Osteonecrosis of the jaw (ONJ) in patients with metastatic breast cancer treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12)
2025 · Andreas Müller, Arnoud J Templeton, et al. · Clinical Cancer Research
P057: TLD-1, a Second-Generation Nano-Liposomal Doxorubicin, in Patients with Advanced Breast Cancer from the Dose Escalation and Expansion Phase 1 Study (SAKK 65/16)
2025 · M. Rabaglio-Poretti, K.-L. Koster, et al. · The Breast
Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib
2022 · Diana Lüftner, Rupert Bartsch, et al. · Cancer Research
200TiP ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor (HER2) positive, early breast cancer (eBC) observing real-life extended adjuvant treatment with neratinib and concurrent use of the eHealth solution CANKADO
2021 · N. Harbeck, D. Lüftner, et al. · Annals of Oncology
PDF
Abstract OT-37-01: Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18
2021 · Michael Schwitter, Khalil Zaman, et al. · Cancer Research
Works count: 28
Citation count: 154
H-index: 8
I10-index: 5
Year
Topic
Type